top 10

Listing : ( NASDAQ : GILD )

Gilead Sciences is at the top of the “ Buy ” lists at most Wall Street firms . Following a successful hepatitis C drug ( Sovaldi ) launch in January , the company continues to build a strong and impressive oncology pipeline . The company also continues to innovate in the HIV arena . The stock closed on Aug . 15 at $ 99.49 . www . gilead . com

46 September 2014